Oruka Therapeutics (ORKA) Operating Expenses (2010 - 2024)

Oruka Therapeutics' Operating Expenses history runs 15 years deep, the most recent figure standing at $3.1 million for Q2 2024.

• On a quarterly basis, Operating Expenses rose 58.24% year-over-year to $3.1 million in Q2 2024; TTM through Mar 2025 was $3.1 million, a 60.89% decrease from a year earlier, with the FY2023 full-year figure at $7.3 million, down 31.14% from the prior year.
• Operating Expenses improved to $3.1 million in Q2 2024 per ORKA's latest filing, from $2.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $5.7 million in Q4 2021 and bottomed at $1.3 million in Q2 2020.
• The 5-year median for Operating Expenses is $2.5 million (2022), against an average of $2.9 million.
• Across the five-year window, Operating Expenses surged 301.1% in 2020 and sank 72.75% in 2022, its largest moves.
• Year by year, Operating Expenses stood at $5.1 million in 2020, then climbed by 10.81% to $5.7 million in 2021, then sank by 72.75% to $1.5 million in 2022, then grew by 2.71% to $1.6 million in 2023, then jumped by 96.35% to $3.1 million in 2024.
• Per Business Quant, the three latest ORKA Operating Expenses figures stand at $3.1 million (Q2 2024), $2.5 million (Q1 2024), and $1.6 million (Q4 2023).